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1. Introduction 
Thyroid Cancer is the third most common solid tumor in children, accounting for 35% of the 
carcinomas in pediatric populations. The reported incidence in the United States is relatively 
low compared to other tumors (approximately 0.2-0.5 per 100,000/year) with a reported age 
adjusted incidence of 8.5 per 100,000. As in adults, the tumors are more frequent in females. 
The female to male incidence ratios vary with age. In children under the age of 10 the ratio is 
1.2:1, in the 10-21 year old group it is 3.6:1(Shapiro, 2005). Overall, 10% of all cases occur in 
patients younger than 21 years and the reported average age at presentation is 11-19 years 
(Shapiro, 2005, Parisi, 2007). 
The initial clinical presentation of pediatric thyroid cancer is usually an asymptomatic mass 
in the neck. Thirty three to fifty percent of those identified neck masses are subsequently 
diagnosed as malignant. Certain characteristic features, such as firmness of the mass and the 
degree of fixation to surrounding tissues, as well as lymphadenopathy and/or vocal cord 
paralysis are associated with an increased probability of malignancy. Pain, tenderness, 
difficulty swallowing and respiratory problems are not typically reported in the majority of 
pediatric patients (Jarzab, 2005). Important risk factors for the development of thyroid 
cancer in children include exposure to external radiation, congenital hypothyroidism and a 
history of prior malignancies (Parisi, 2007, Niedziela, 2006).  
The location of well-differentiated tumors (WDTC) in the gland is variable; however the 
majority (68%) of the reported malignancies are localized in the right lobe. Children with 
thyroid tumors are generally clinically euthyroid (Jarzab, 2005).  
The four main histologic types of pediatric thyroid cancers are papillary, papillary-follicular 
variant, follicular (FTC), and medullary carcinoma. The majority of the tumors (90-95%) are 
classified as well differentiated type, i.e., papillary and follicular type (Niedziela, 2006). 
Medullary tumors are diagnosed in 5-8% of the patients and produce calcitonin. Medullary 
carcinomas arise from the parafollicular cells or C cells while the papillary and follicular 
tumors originate from the follicular epithelium. Medullary tumors will be discussed later in 
the chapter. 
Papillary thyroid tumors (PTC) are larger in pediatric patients as compared to tumors in 
adults at presentation. Capsular invasion is seen in 67% of the pediatric patients (Parisi, 
2007, Niedziela, 2006). Unlike adults, pediatric patients often present with extensive regional 
nodal disease and distant metastasis at diagnosis. Cervical nodal disease ranges from 60-
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90%; distant metastasis occurs in 13-23%, most commonly to the lung (Parisi, 2007, Jarzab, 
2005). Tracheoesophageal nodes are the ones most frequently involved, followed by the mid 
jugular and the lower deep jugular group. Bulky nodal metastasis may be associated with 
small tumors, 1cm or less. Lung metastasis occurs more frequently in patients with extra 
capsular invasion, bilateral tumors and patients below age 7 at diagnosis. Pulmonary 
metastases in children are typically miliary and rarely nodular as opposed to adults. 
Metastases to the lungs are functional in 95% of the cases (Luster, 2007, Mitsutake, 2005). 
This is related to greater expression of the sodium iodide symporter (NIS) in pediatric 
thyroid cancers. The increased expression of NIS in pediatric tumors implies a greater 
degree of differentiation compared to adult papillary cancers. Long-term survival is also 
poorer; however the reported difference in survival is narrow (Shapiro, 2005). 
2. Diagnosis  
Thyroid tumors are suspected by a history of an anterior neck palpable mass with or 
without hoarsenes . Further imaging evaluation studies should include thyroid ultrasound 
which is the method of choice for the assessment of nodular disease. It is a rapid, safe, 
noninvasive, and readily available technique. In addition, sonographic evaluation helps to 
distinguish cystic from solid lesions and allows guidance for fine needle aspiration biopsy 
(FNA). The sonographic appearance of thyroid cancer varies with the histologic type. PTC 
lesions are usually solid and hypoechoic with (i.e., 70% of the affected) increased vascularity 
and micro calcifications. The presence of microcalcifications is highly specific for PTC. On 
the other hand, FTC is more frequently iso- or hyperechoic with a thick and irregular halo. 
The latter appearance associated with the presence of suspicious regional lymph nodes 
increases the risk of malignancy in pediatric thyroid nodules. However, the presence of 
cystic lesions should not be ignored since 50% of all malignant thyroid lesions have a cystic 
component and 8% of sonographic cystic lesions represent neoplasia (Niedziela, 2006,Jarzab, 
2005,Luster, 2007).  
Presently ultrasound-guided fine needle aspiration (FNA) is the most reliable and cost 
effective method to establish a cytologic diagnosis in up to 73% of lesions prior to surgery. 
Specifically, a true positive diagnosis can be obtained in up to 90% of the lesions with PTC. 
However, in children FNA accuracy may be less than in adults as reported by Parisi & 
Niedziela. Therefore, a negative FNA must be interpreted with caution and it should not be 
used as the sole predictor of malignancy.  
Nuclear thyroid scintigraphy with 99mTc-pertechentate or 123-Iodine may be used in the 
initial evaluation. It helps in the identification of the “cold nodule”, a lesion described as a 
well-defined area with less radiotracer uptake as compared to normal tissue. It must be 
remember that only 10-15% of cold lesions in a thyroid scintiscan are malignant, meaning that 
sonographic guided FNA is needed for a definite diagnosis. In addition, lesions less than 1 cm 
may be missed, an important limitation of nuclear thyroid imaging to bear in mind.  
Immunocytochemical studies are used to further improve the diagnosis. Several tumor 
markers have been studied in an attempt to enhance diagnosis. Among these are telomerase, 
galactin-3 and cytokeratin-19. Unfortunately, none have been able to distinguish benign 
from malignant lesions in children, particularly in cases of follicular tumors or follicular 
variant of papillary thyroid cancer (Xu, 2003, Mitsutake, 2005).  
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Recently, interest has focused on genetic markers as a diagnostic tool since they might have 
a role in terms of tumor behavior. Kimura et al (2003) studied 177 cases of PTC and found 
RET, NTRK, BRAF and/or RAS mutations in 70% of the tumors. Namba et. al. (2003) 
reported that papillary lesions with BRAF gene mutation have more aggressive 
extrathyroidal invasion with less favorable prognosis. This is more frequently seen in the 
columnar type and the classic PTC variant (Xu, 2003, Mitsutake, 2005). It leads to the origin 
of oncogene BRAF which activates MAPK kinase. Activation of this cascade has the effect of 
inappropriate cell proliferation and differentiation into neoplasia.  
Other investigators have reported over expression of MET in papillary cancers. Together 
with the tyrosine kinase receptor ligand it is associated to a higher recurrence risk in 
children. Gupta (2001) et al found that patients with PTC with the greatest number of 
proliferating lymphocytes in thyroid infiltrates have the longest disease free survival 
(Jarzab, 2005, Griffith 2006). On the other hand, patients with intense expression of B7-2 
antigen had a greater propensity for recurrence (Jarzab, 2005). Kroll et. al. identified a 
mutation in follicular thyroid cancers - twenty to fifty percent of them harbor an 
interchromosomal translocation that fuses PAX8 to PPARγ. This acts as an oncoprotein. FTC 
that do not have PAX8 / PPARγ recombination are often associated with RAS mutations 
(Xu, 2003,Mitzutake, 2005,Griffith, 2006).  
3. Tumor staging 
The American Thyroid Association (ATA) published in 2009 the guidelines for the 
management of thyroid nodes and differentiated thyroid cancer. Using the TNM 
classification pediatric thyroid cancer is classified as a TNM stage I or II, according to the 
presence or absence of distant metastasis regardless of the existence of lymph node 
metastases.  
It is recognized that pediatric thyroid cancer at diagnosis often involves spread to lymph 
nodes as well as distant metastasis. Based on these characteristics at diagnosis, some authors 
have recommended the use of a sub stage classification that takes into consideration major 
risk factors such as gender, multifocality, lymph node invasion, distant metastasis and 
young age. Based on the frequency of extensive disease, lymph node and the presence of 
distant metastasis and the high recurrence rate,  most children should be included in the 
high risk  group, even when most staging systems classify them in Stage 1 or  Stage 2 
(Wada, 2009). 
4. Surgical treatment 
Treatment of WDTC is intended to eradicate disease and improve recurrence free survival. 
The primary treatment modality remains surgical excision followed by radioiodine ablation 
and thyroid hormone suppression therapy; a paradigm followed in many institutions.  
The extent of surgical removal is still a matter of debate in many places. The ATA and the 
American Association of Clinical Endocrinologists have recommended a total or near total 
thyroidectomy if feasible in most of the cases (Cooper, 2009). Total thyroidectomy remains 
the preferred operation in tumors greater than T1a (>1cm). It is generally accompanied by 
dissection of the central lymphatic compartment since local lymph node disease increases 
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the risk of local and regional recurrence (Parisi, 2007, Niedziela, 2006, Handkiewicz, 2007). 
Patients who undergo total thyroidectomy have a higher rate of recurrence-free survival. 
Patients with intrathyroidal lesions less than 1cm can be considered candidates for less than 
total thyroidectomy if the lesion is unifocal, there is no previous history of radiation 
exposure, and there is no evidence for either lymph node or distant metastasis at diagnosis.  
Complications of surgery are rare in the hands of experienced surgeons. The most common 
complication is parathyroid dysfunction, resulting in hypocalcemia and low serum PTH 
concentrations. The hypoparathyrodism is usually transient and resolves in several weeks 
with some patients requiring temporary treatment. A more serious complication is the 
irreversible damage to the recurrent laryngeal nerve causing permanent vocal cord paralysis 
and hoarseness; however, in our practice we have never seen such a case. Nowadays the use 
of intraoperative probe reduces surgical time and complications.  
4.1 Post-surgical evaluation and radioiodine treatment 
A sonographic evaluation is advisable to assess the size of the thyroid remnant and 
determine the adequacy of excision after surgery. Images should depict a volume of less 
than 2 ml of thyroid tissue at approximately 1 month after its removal.  
Thyroid ablation with radioiodine (RAI) is routinely recommended to destroy any residual 
tissue after surgery. The goal of the postsurgical treatment is to ablate the thyroid remnant 
and evaluate the extent of functional thyroid tissue and/or metastatic disease. The 
radioiodine dose should be individualized and is often empirically adjusted to tumor size 
and disease extension. Therefore, RAI doses ranging from 30-200 mCi (1.1-7.4 GBq) have 
been employed. The use of low dose vs. high dose treatments is still a debated issue, since 
some authors claim there is little difference in efficacy between the 30mCi and the 100 mCi. 
The higher activity is more effective in detecting and treating metastatic disease. In our 
practice we use doses in the pediatric population similar to those in adults. For patients with 
disease extension to neck nodes we recommend 100mCi (3.7 GBq) and for patients with 
distant metastasis we have used 150-200 mCi (5.6-7.4 GBq). We pursue Whole Body Scan 
(WBS) post therapy usually 5-7 days after the therapeutic radioiodine dose. In most patients, 
the WBS demonstrates post surgical residual functioning tissue in the thyroid bed, 
additional loco-regional nodes or distant metastases. Post therapy scintigraphy may detect 
new lesions in up to 46% of the cases (Silva, 2010) . 
Thyroid ablation therapy reduces the risk of recurrence in the thyroid bed and neck lymph 
nodes, independent of the extent of the surgical procedure. Both treatment modalities 
(surgery and RAI ablation) are independent predictors of recurrence free survival. Local 
relapse is reduced to 6.3% when 131-I is administered after surgery. Recurrence rate in the 
thyroid bed and local lymph nodes is also reduced when total thyroidectomy and ablation 
therapy are given. This is especially important in the pediatric population given their longer 
life expectancy. It has been found that sex, age and histology do not correlate with thyroid 
bed recurrence free survival. Nodal recurrences are more frequent in patients with the 
histologic subtype of papillary carcinoma, classical variant as compared to the follicular 
variant. Specifically, the 10 year nodal recurrence free survival has been reported at 83% for 
papillary carcinoma, classic type vs. 95% for the follicular variant type (Parisi, 2006, Luster, 
2007, Handkiewicz, 2007). 
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In patients with lung metastasis, there is often incomplete post therapy remission. Several 
authors have reported a high incidence of persistent disease after therapeutic iodine in 
patients with lung metastasis. Repeated courses of ablation therapy is often needed. Since 
ablation therapy could have adverse effects on the lungs (i.e., pneumonitis with fibrosis), it 
is important to monitor pulmonary function in this population.  
The tumor response to RAI therapy is related to the size of the residual tissue or tumor 
burden. Tumoral masses with small volume (i.e., less than 1 mm) in children results in 
poorer therapeutic response. This is related to the effect of the iodine beta radiation range, as 
established in the Monte Carlo simulation test published by Reynolds, Robbins and Maxon. 
Approximately 90% of the ionizing radiation emitted by the 131-iodine decay will be 
absorbed outside the tumor range (Silva, 2010).  
Juvenile thyroid cancer is known to have a high recurrence rate. The rate may be as high as 
40% in patients less than 20 years of age and higher within the first 7 years of diagnosis. 
Twenty year recurrence free survival is about 10% in patients diagnosed at age 10 or less. In 
fact, age is a major determinant of risk of recurrence, particularly in those younger than 10 
years (Niedziela, 2006, Jarzab, 2005). Overall younger patients have a poorer prognosis than 
those diagnosed later in life. In spite of these data, it should be emphasized that prognosis is 
still excellent with an overall survival rate of 95% for over a 12.9 years of follow up in large 
series (Shapiro, 2005, Parisi, 2007). 
Five and ten year survival rates in pediatric patients with thyroid cancer have been reported 
as high as 98-99%. However, the mortality rate may become significant in cases with distant 
metastasis or recurrent disease. In the latter, the cumulative mortality rate varies from 30-
58% in a period of 12-20 years.  
Over the last several years, FDG-PET studies have been included in the armamentarium of 
diagnostic tests in the follow up of patients with thyroid cancer. PET imaging is 
recommended in selected cases only, specifically those with negative iodine WBS and 
positive or rising thyroglobulin levels. FDG uptake can identify recurrent disease in up to 
70-80% of those cases; uptake is associated with a poor outcome and decreased survival 
(Parisi, 2007).  
5. Risks of radioiodine therapy in the pediatric population 
Radioiodine therapy can have complications, both in the short and in the long term. Short 
term complications include nausea, sialadenitis, pain and swelling in the neck. The 
frequency of these varies from 10-50%. Long term effects are related to the radiation-
induced mutations (i.e., radiation carcinogenesis). These are of utmost importance given the 
long life expectancy the pediatric group has at the time of diagnosis.  
In terms of the gonadal axis, RAI therapy is associated with an earlier menopause compared 
with the general female population. In males azoospermia and oligospermia have been 
described. Increased risks of secondary malignancies, mainly solid tumors and leukemias, 
have also been reported. Pulmonary fibrosis has been reported in patients with extensive 
pulmonary metastasis; in fact up to 10% of pediatric patients can develop pulmonary 
fibrosis. All of the above complications are dose dependent (Parisi, 2007).  
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6. Follow up  
Hormonal suppressive therapy follows the ablation therapy and is aimed at reducing the 
risk of tumor re growth and recurrences. The recommended TSH suppression level may be 
in the range of 0.1-0.5 mU/L and should be dependent on the presence or absence of 
persistent disease.  
Serum thyroglobulin (Tg), a tumor specific marker, is a valuable assay during follow up. Tg 
is only produced by the follicular cells. After thyroidectomy, Tg should be undetectable. The 
assay of thyroglobulin is recommended before ablation therapy (under TSH stimulation) 
and 6-12 months after therapy (on suppression). The predictive value for disease 
progression is well established in the literature. 
Stimulated levels of serum thyroglobulin more than 2 or 3 ng/ml after recombinant TSH are 
considered diagnostic of tumor recurrences. A rising value of Tg alerts the clinician to the 
presence of active disease and is more sensitive if the sample is measured after TSH 
stimulation. It is recommended to have the samples analyzed in the same laboratory using 
the same assay method. Thyroglobulin antibodies (TgAb) must be determined in the same 
serum sample since the presence of TgAb invalidates the thyroglobulin results. (Goldsmith, 
2011).  
Some authors have reported that Tg use is not completely reliable for follow up purposes. 
Specifically, they do not advocate the sole use of Tg as a method for follow up in affected 
patients when screening for persistent or recurrent disease. False negative Tg values have 
been reported in 4-35% of the patients with evidence of local or metastatic disease. 
Undetectable serum Tg has been reported in patients treated with RAI, with small volumes 
of disease. Other reasons associated with the low or undetectable Tg levels are the presence 
of TgAb, immunologically inactive Tg or technical limitations of the assay method. Thus, 
relying on Tg values as a single criterion in the long term follow up of thyroid cancer should 
be exercised with caution. In our center, pediatric patients are evaluated annually for at least 
three consecutive years and thereafter every two or three years depending on the clinical 
follow up evaluation. All patients are evaluated withTg and Tg Ab levels as well as a neck 
ultrasound. Neck ultrasound is an excellent tool for the early detection of neck nodal 
metastasis and should be used in conjunction with the Tg measurement in the follow up of 
patients whenever possible (Parisi, 2007, Niedziela, 2006, Jarzab, 2005). In our clinic, patients 
with initial distant metastasis, 131-I Whole body scan is done one year after the therapeutic 
dose to determine if an adittional therapeutic doses is necessary. Clinical follow up is 
recommended until adulthood.  
7. Medullary Thyroid Carcinoma 
Medullary thyroid carcinoma (MTC) originates in calcitonin-producing cells (C-cells) of the 
thyroid gland and accounts for 3% to 9% of thyroid cancers. MTC is diagnosed 
histologically when nests of C-cells appear to extend beyond the basement membrane and 
infiltrate and destroy thyroid follicles. At least half occur in kindreds and are apparently 
inherited as an autosomal dominant trait. It may be part of multiple endocrine neoplasia 
type 2 (MEN 2) including the phenotypes MEN 2A, familial medullary thyroid carcinoma 
(FMTC), and MEN 2B. 
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MTC in persons with MEN 2 typically present at a younger age than sporadic MTC and is 
more often associated with C-cell hyperplasia as well as multifocality or bilaterality. 
Symptoms of MTC include neck pain, a palpable neck mass, and/or diarrhea resulting from 
hypercalcitoninemia [Callender et al 2008]. Metastatic spread to cervical and regional lymph 
nodes (i.e., parathyroid, paratracheal, jugular chain, and upper mediastinum) or to distant 
sites including the liver, lungs, or bone is common and is frequently present in individuals 
with a palpable thyroid mass or diarrhea [Cohen & Moley 2003]. 
The responsible mutated gene causing inherited MTC is the ret tyrosine kinase which has 
been mapped to 10q11.2.  
The FMTC subtype constitutes approximately 10%-20% of cases of MEN 2. By operational 
definition MTC is the only clinical manifestation of FMTC. The age of onset of MTC is later 
in FMTC and the penetrance of MTC is lower than that observed in MEN 2A and MEN 2B 
[Eng et al 1996, Machens et al 2001, Machens & Dralle 2006, Zbuk & Eng 2007, American 
Thyroid Association Guidelines Task Force 2009].  
The MEN 2B subtype accounts for approximately 5% of cases of MEN 2. MEN 2B is 
characterized by the early development of an aggressive form of MTC in all affected 
individuals [Skinner et al 1996]. Individuals with MEN 2B who do not undergo 
thyroidectomy at an early age (age <1 year) are likely to develop metastatic MTC at an early 
age. Prior to intervention with early prophylactic thyroidectomy, the average age of death in 
individuals with MEN 2B was 21 years. 
The American Thyroid Association Guidelines Task Force has classified mutations based on 
their risk for aggressive MTC [American Thyroid Association Guidelines Task Force 2009]. 
The classification may be used in (1) predicting phenotype and in (2) recommendations 
regarding the ages at which to (a) perform prophylactic thyroidectomy and (b) begin 
biochemical screening for pheochromocytoma and hyperparathyroidism. Annual 
biochemical screening for MEN 2A beginning at age eight years has been recommended for 
individuals with mutations of codons 630 and 634 and at age 20 years for mutations in all 
other codons [American Thyroid Association Guidelines Task Force 2009]. Screening for 
FMTC is indicated just as for patients in kindreds with MEN 2. MEN 2B patients identified 
by genetic screening should undergo thyroidectomy at 6 months of age. However screening 
should not be precluded and still be pursued early in life in children at risk of carrying MEN 
2B genes since disease manifestation could be aggressive and devastating. The best time for 
surgery should be individualized (author personal experience). A basal or stimulated 
calcitonin level of ≥100 pg/ml is an indication for surgery [Costante et al 2007, American 
Thyroid Association Guidelines Task Force 2009]. 
The standard treatment for MTC is surgical removal of the thyroid and lymph node 
dissection [American Thyroid Association Guidelines Task Force 2009]. Chemotherapy and 
radiation are less effective in the treatment of MTC than surgical removal [Moley et al 1998, 
Cohen & Moley 2003]. All individuals who have undergone thyroidectomy need thyroid 
hormone replacement therapy. Autotransplantation of parathyroid tissue is not typically 
performed at the time of thyroidectomy unless there is evidence of hyperparathyroidism 
[American Thyroid Association Guidelines Task Force 2009]. Prophylactic thyroidectomy is 
the primary preventive measure for individuals with an identified germline RET mutation 
[American Thyroid Association Guidelines Task Force 2009]. Prophylactic thyroidectomy is 
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safe for all age groups; however, the timing of the surgery is controversial. According to the 
consensus statement from the American Thyroid Association Guidelines Task Force, the age 
at which prophylactic thyroidectomy is performed can be guided by the codon position of 
the RET mutation. These guidelines continue to be modified as more data becomes 
available. 
For all individuals with a RET mutation who have not had a thyroidectomy, annual 
biochemical screening with calcitonin is recommended with immediate thyroidectomy if 
results are abnormal [Szinnai et al 2003]. Annual serum calcitonin screening [American 
Thyroid Association Guidelines Task Force 2009] should begin for children with: MEN 2B at 
age six months and MEN 2A or FMTC at age three to five years. Caution should be used in 
interpreting calcitonin results for children younger than age three years, especially those 
younger than age six months. Prophylactic thyroidectomy should not be offered routinely to 
at-risk individuals in whom the disorder has not been confirmed. RET gene molecular 
genetic testing should be offered to probands with any of the MEN 2 subtypes and to all at-
risk members of kindreds in which a germline RET mutation has been identified in an 
affected family member.  
Alternate therapies are still under investigation with potential benefits in the near future. 
Among these:  Adenoviral vectors expressing a dominant-negative truncated form of RET, 
DeltaTK; potential of tyrosine kinase inhibitors, such as vandetanib. 
8. Conclusion 
Well differentiated is the most common pediatric thyroid cancer and usually presents as a 
solitary mass. The disease is frequently extensive at diagnosis. Surgical management is 
important for the initial control of the disease, follow by radioiodine therapy. High 
therapeutic radioiodine doses are required in the majority of the cases. Long term follow up 
with hormonal suppressive therapy is recommended. Neck sonogram and serum 
thyroglobulin level is recommended for the first 3 consecutive years. In spite of the 
extensive disease, overall long term survival in these patients is excellent. 
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